Lee, Lui Shiong
Sim, Adelene Y. L.
Ong, Chee Wee
Yang, Xinyan
Ng, Cedric C. Y.
Liu, Wei
Rajasegaran, Vikneswari
Lim, Abner M. S.
Aslim, Edwin Jonathan http://orcid.org/0000-0003-1512-3356
Ngo, Nye-Thane http://orcid.org/0000-0003-2419-0817
Khor, Li-Yan
Kanesvaran, Ravindran
Allen, John Carson Jr
Tay, Kae Jack http://orcid.org/0000-0003-0365-1899
Yuen, John Shyi Peng
Chong, Tsung Wen
Ho, Sun Sien Henry
Teh, Bin Tean
Chua, Melvin L. K. http://orcid.org/0000-0002-1648-1473
Funding for this research was provided by:
MOH | National Medical Research Council (NMRC/CSA-INV/0027/2018, MOH-000248)
National Research Foundation Singapore (NRF-CRP17-2017-05)
Ministry of Education - Singapore (MOE2016-T3-1-004)
National Cancer Centre of Singapore
Duke-NUS Medical School
Sengkang General Hospital
Article History
Received: 5 November 2021
Revised: 3 January 2022
Accepted: 12 January 2022
First Online: 28 January 2022
Change Date: 14 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41391-022-00522-9
Competing interests
: LLS received clinical trial funding from Janssen, honorarium arising from ad hoc medical advisory boards for Astellas, Janssen, Bayer, and MSD, and is a consultant for BIoCheetah. MLKC reports personal fees from Astellas, Janssen, Bayer, Pfizer, MSD, personal fees and non-financial support from AstraZeneca, personal fees and grants from Ferring, personal fees and non-financial support from Varian, non-financial support from Decipher Biosciences, non-financial support from MedLever, non-financial support from EVYD Technology, and consults for immunoSCAPE Inc., outside the submitted work. RK received honorarium from ad hoc medical advisory boards for Janssen, Astellas, BMS, MSD, Bayer, Ferring, Amgen, Pfizer, Novartis, AstraZaneca, Eisai, and Ipsen.